Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

135 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The catalytic subunit of DNA-PK regulates transcription and splicing of AR in advanced prostate cancer.
Adamson B, Brittain N, Walker L, Duncan R, Luzzi S, Rescigno P, Smith G, McGill S, Burchmore RJ, Willmore E, Hickson I, Robson CN, Bogdan D, Jimenez-Vacas JM, Paschalis A, Welti J, Yuan W, McCracken SR, Heer R, Sharp A, de Bono JS, Gaughan L. Adamson B, et al. Among authors: rescigno p. J Clin Invest. 2023 Nov 15;133(22):e169200. doi: 10.1172/JCI169200. J Clin Invest. 2023. PMID: 37751307 Free PMC article.
Paclitaxel in pretreated metastatic penile cancer: final results of a phase 2 study.
Di Lorenzo G, Federico P, Buonerba C, Longo N, Cartenì G, Autorino R, Perdonà S, Ferro M, Rescigno P, D'Aniello C, Matano E, Altieri V, Palmieri G, Imbimbo C, De Placido S, Mirone V. Di Lorenzo G, et al. Among authors: rescigno p. Eur Urol. 2011 Dec;60(6):1280-4. doi: 10.1016/j.eururo.2011.08.028. Epub 2011 Aug 22. Eur Urol. 2011. PMID: 21871710 Clinical Trial.
Long lasting response to second-line everolimus in kidney cancer.
Virtuoso A, Policastro T, Izzo M, Federico P, Buonerba C, Rescigno P, Di Lorenzo G. Virtuoso A, et al. Among authors: rescigno p. World J Clin Cases. 2013 Aug 16;1(5):166-8. doi: 10.12998/wjcc.v1.i5.166. World J Clin Cases. 2013. PMID: 24303493 Free PMC article.
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: rescigno p. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.
Cytosolic phosphorylated EGFR is predictive of recurrence in early stage penile cancer patients: a retropective study.
Di Lorenzo G, Perdonà S, Buonerba C, Sonpavde G, Gigantino V, Pannone G, Quarto G, Ferro M, Gaudioso G, Terracciano D, Di Trolio R, Rescigno P, Botti G, De Placido S, Facchini G, Ascierto PA, Franco R. Di Lorenzo G, et al. Among authors: rescigno p. J Transl Med. 2013 Jul 2;11:161. doi: 10.1186/1479-5876-11-161. J Transl Med. 2013. PMID: 23819610 Free PMC article.
Activity and toxicity of paclitaxel in pretreated metastatic penile cancer patients.
Di Lorenzo G, Cartenì G, Autorino R, Gonnella A, Perdonà S, Ferro M, Longo N, Rescigno P, Doria F, Faiella A, Altieri V, Palmieri G, Imbimbo C, Mirone V, De Placido S. Di Lorenzo G, et al. Among authors: rescigno p. Anticancer Drugs. 2009 Apr;20(4):277-80. doi: 10.1097/CAD.0b013e328329a293. Anticancer Drugs. 2009. PMID: 19262371 Clinical Trial.
Peg-filgrastim and cabazitaxel in prostate cancer patients.
Di Lorenzo G, DʼAniello C, Buonerba C, Federico P, Rescigno P, Puglia L, Ferro M, Bosso D, Cavaliere C, Palmieri G, Sonpavde G, De Placido S. Di Lorenzo G, et al. Among authors: rescigno p. Anticancer Drugs. 2013 Jan;24(1):84-9. doi: 10.1097/CAD.0b013e32835a56bc. Anticancer Drugs. 2013. PMID: 23044721
Potential value of Gleason score in predicting the benefit of cabazitaxel in metastatic castration-resistant prostate cancer.
Buonerba C, Pond GR, Sonpavde G, Federico P, Rescigno P, Puglia L, Bosso D, Virtuoso A, Policastro T, Izzo M, Vaccaro L, Ferro M, Aieta M, Perdonà S, Palmieri G, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: rescigno p. Future Oncol. 2013 Jun;9(6):889-97. doi: 10.2217/fon.13.39. Future Oncol. 2013. PMID: 23718309
135 results